ArticleInternational journal of molecular sciences2025
The P2X7 Receptor Regulates IL-1β Secretion in the Human Retina.
Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The P2X7 receptor has been associated with the neurodegeneration of retinal ganglion cells (RGCs), which is central to the loss of vision in glaucoma. Furthermore, the activation of P2X7 has been shown to cause the death of RGCs, including in the human retina. Human organotypic retinal cultures (HORCs) were used to investigate the potential indirect mechanisms of RGC death. Of the 27 cytokine/growth factors assayed, the stimulation of P2X7 using BzATP (100 µM; 36 h) significantly increased the secretion of IL-1β and IL-10. IL-1β was selected for further investigation. BzATP (100 µM) caused an increase in the expression and release of IL-1β in a time-dependent manner; this increase was inhibited through a co-incubation with BBG (1 µM). Exogenous IL-1β alone (10 ng/mL) did not cause a loss of RGCs. However, IL-1β inhibited the loss of RGCs caused by BzATP, and this neuroprotection was prevented by the Interleukin-1 receptor-1 antagonist (IL-1ra) (100 ng/mL). The IL1 receptor IL-1R1 was localised to the inner retina close to the RGCs, although not predominantly co-localised with RGC bodies. The results suggest that the P2X7-mediated death of RGCs is not IL-1β mediated. Furthermore, IL-1β may be upregulated as part of a response to mitigate P2X7-mediated damage to the retina. Our research is the first to indicate the P2X7-mediated regulation of IL-1β in the human retina and supports the role of the ATP/P2X7/IL-1β axis in RGC survival and possible glaucomatous RGC degeneration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.